Full year 2009 sales for DSM declines 11% as a result of low demand from pharmaceutical companies, delay in approvals and the loss of some large contracts. In addition the company recognised a non-cash goodwill impairment charge of €154m from its acquisition of Catalytica.
DSM
Wednesday 24 February 2010
Pharma sales decline at DSM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment